DERMATOPHYTIC ONYCHOMYCOSIS TREATMENT MARKET ANALYSIS

Dermatophytic Onychomycosis Treatment Market, By Product Type (Tablets(Rx, OTC)Mail Paints(Rx, OTC)), By Treatment (Oral, Topical), By End User (Hospitals, Clinics, Independent Pharmacies, Mail Order Pharmacies, Drug Stores), and by Regions (North America, Latin America, Europe, Asia Pacific, Middle East and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

Published In : Dec 2019
Code : CMI2053
Pages :210
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Global Dermatophytic Onychomycosis Treatment Market: Competitive Landscape

Major players operating in the global dermatophytic onychomycosis treatment market include, Valeant Pharmaceuticals International Inc., Galderma S.A., Novartis AG, Pfizer Inc., Moberg Pharma AB, Janssen Global Services, LLC (Johnson & Johnson Services, Inc.), Anacor Pharmaceuticals, Inc., NovaQuest Capital Management, L.L.C., and Novan, Inc.

Global Dermatophytic Onychomycosis Treatment Market: Key Developments

Key players in the market are focused on conducting clinical trials in order to expand their product portfolio. For instance, in December 2019, Moberg Pharma AB announced that MOB-015 (topical terbinafine) met both primary and key secondary endpoints of the clinical Phase 3 study that assessed the efficacy and safety of MOB-015 in patients with mild to moderate distal subungual onychomycosis.